Browse by author
Lookup NU author(s): Dr Janet Grace,
Professor Ian McKeith
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
Patients with dementia with Lewy bodies (DLB) have progressive deficits in cognition, parkinsonism, and neuropsychiatric symptoms. Cholinesterase inhibitors have been used to ameliorate cognitive decline and neuropsychiatric symptoms in short-term trials. In this study, patients with DLB were treated with rivastigmine up to 96 weeks. Improvement from baseline was seen in cognitive function as measured by the Mini-Mental State Examination (MMSE), and neuropsychiatric symptoms as measured by the Neuropsychiatric Inventory (NPI) over the first 24 weeks of treatment. By 96 weeks, neither the MMSE scores nor the NPI scores were significantly worse than at baseline.
Author(s): Grace J, Daniel S, Stevens T, Shankar KK, Walker Z, Byrne EJ, Butler S, Wilkinson D, Woolford J, Waite J, McKeith IG
Publication type: Article
Publication status: Published
Journal: International Psychogeriatrics
ISSN (print): 1041-6102
ISSN (electronic): 1741-203X
Publisher: International Psychogeriatric Association and Cambridge University Press
Altmetrics provided by Altmetric